Visual snow syndrome, a condition causing static-like vision impairment, allegedly connects Idaho murderer Bryan Kohberger ...

This is an overview of systematic reviews to evaluate the visual outcomes of different presbyopia correcting intraocular lens ...

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast ...

Study met primary endpoint of ≥15-letter (≥3-line) gain in mesopic low contrast distance visual acuity in comparison to placeboPhase 3 study showed patient-reported functional benefit in ...

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive top-line results from LYNX-2, a pivotal Phase 3 trial evaluating MR-142 (phentolamine ophthalmic solution 0.75% ...

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast ...

Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions ...

Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions ...

From blank stares to visual disturbances, know the lesser-known symptoms of epilepsy that often go unnoticed.

The Key Night Vision Disturbances Companies in the market include - Ocuphire Pharma/Viatris, and others. DelveInsight’s “Night Vision Disturbances Market Insights, Epidemiology, and Market ...